Merck has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer

03-Aug-2009 - Germany

Merck KGaA announced that it has requested re-examination of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the first-line treatment of patients with non-small cell lung cancer (NSCLC). Taking the opinion seriously Merck will work closely with the CHMP to unravel the value of Erbitux for patients benefit most.

The decision to request re-examination follows consultation with key stakeholders in the NSCLC treatment community, coupled with Merck’s confidence in the clinical data supporting Erbitux in this potential indication.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances